Address: Georg-Glock-Straße 8, 40474 Düsseldorf,Germany
Tel: 0211 – 5 86 01-00
Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of therapeutic, corrective and aesthetic solutions in dermatology. Its expertise spans a broad spectrum of skin, hair and nail diseases. Founded in 1981, Galderma is a joint venture between Nestlé and L’Oréal and employs close to 3.000 people. The company, headed by President & CEO Humberto C. Antunes, has wholly-owned affiliates in 31 countries and a worldwide network of exclusive sales agents. The parent company is based in Lausanne, Switzerland, with Corporate Services in Paris-La Défense, France. In 2008, sales reached 854 million euros, an increase of + 22.4%* over 2007.To drive sustained growth, Galderma invests around 20 percent of revenues in innovation for the development of drugs and other medical solutions which are sourced internally from its own research activities or from partnerships. The R&D staff operates out of 3 specialized sites in the USA, France and Japan.With products sold in more than 65 countries and promoted by a sales force of around 1.000 representatives, Galderma is providing a wide range of innovative medical solutions meeting the highest standards of safety and efficacy. Committed to the future of dermatology, Galderma’s ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meetings the needs of dermatology patients and physicians.
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
As head of digital transformation at Bayer, Saskia Steinacker is well placed to unpack the hype around artificial intelligence in healthcare. In a wide-ranging interview, she explains how AI is…
Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector.…
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
See our Cookie Privacy Policy Here
